Daily Market Commentary for October 22, 2012
Reports released on Monday implicates Monster Beverage Corp. (MNST) energy drinks as a possible factor in the recent deaths of five people.
(read more at Millennium-Traders.Com)http://www.millennium-traders.com/news/newscommentary.aspx
Caterpillar Inc.'s (CAT) on Monday reported Q3 earnings rose 49% but, lowered its 2012 outlook amid weaker-than-expected global economic conditions. CAT now expects per-share earnings of $9 to $9.25 on revenue of nearly $66 billion, compared with prior estimate for earnings of nearly $9.60 with revenue from $68 billion to $70 billion. Caterpillar reported a profit of $1.7 billion or $2.54 a share, up from $1.14 billion, or $1.71 a share, for same period in 2011. The latest period included a $273 million gain from the sale of its third-party logistics business. Revenue increased 4.6% to $16.45 billion while operating margin rose to 15.8% from 11.2%. For 2013, CAT expects sales and revenue to be nearly the same as 2012, plus or minus 5%. The construction and mining equipment maker benefited from an asset-sale gain and posted continued revenue growth. As the world's largest manufacturer of bulldozers, excavators and other construction machinery, Caterpillar is closely watched as a gauge of the strength of the global economy. "We are taking a pragmatic view of 2013--we're not expecting rapid growth, and we're not predicting a global recession," said Chairman and Chief Executive Doug Oberhelman. "While machine deliveries to end users have continued to hold up, our sales will probably remain relatively weak early in 2013 as dealers are likely to continue reducing inventories."
Supernus Pharmaceuticals Inc. (SUPN) said Monday the U.S. Food and Drug Administration gave final approval for its once-daily extended-release epilepsy treatment, Oxtellar - an extended-release formulation of oxcarbazepine, is indicated as an adjunctive therapy in the treatment of partial seizures in adults and in children six to 17 years of age. Supernus Pharmaceuticals focus on developing and commercializing products for diseases of the central nervous system. The received a waiver from the FDA for the pediatric-study requirement for ages birth to one month and a deferral for submission of post-marketing assessments for children ages one month to six years. Its other products in development include treatments for attention deficit hyperactivity disorder, or ADHD. he company also received tentative approval for its Trokendi XR epilepsy treatment. The Pharmaceutical firm has delayed plans to launch Trokendi XR to Q3 2013 from the end of 2012 on expectations that final FDA approval may not be made effective until a marketing-exclusivity period expires. Supernus shares were higher by at least 18% in pre-market trading Monday but ended the session down less than one percent, as the markets tumbled during the session.
Eli Lilly & Co.'s (LLY) announced their investigational once-weekly diabetes treatment showed positive results in lowering overall blood glucose levels in a series of Phase III studies. In three long-term studies ranging from 26 weeks to two years, dulaglutide for type 2 diabetes, showed improved glycemic control when compared with a placebo and with other diabetes drugs. At scientific meetings in 2013 and 2014, Lilly plans to give more details regarding the dulaglutide data. Lilly said the timing of its application for U.S. approval depends on satisfactory completion of U.S. Food and Drug Administration requirements for assessment of cardiovascular risk and plans to seek regulatory approval next year. Lilly shares ended the trading session on Monday, down slightly over 1%.
Transcatheter aortic valve implantation system, CoreValve, from Medtronic Inc. (MDT) medical-device maker said studies showed it improved patients' one-year survival rate and quality of life, while its Symplicity system for renal denervation reduced patients' blood pressure after two years. Medtronic said initial one-year results of Advance study showed that patients implanted with the CoreValve System had a survival rate of 82.1% and a cardiovascular survival of 88.2%. "Transcatheter aortic valve implantation already has been shown to improve survival compared with standard therapy, but quality of life can be at least as important as survival in elderly patients, especially since TAVI patients can be frail with multiple comorbidities," said Johan Bosmans, professor at the University Hospital of Antwerp in Belgium. "We are extremely proud of this data which confirms that the benefits of transcatheter aortic therapy extend beyond survival even in this challenging patient population." Health-related quality of life measures also improved significantly at one and six months with the Advance study evaluating 996 patients at 44 TAVI centers in 12 countries. Medtronic also reported that Symplicity HTN-1, a series of pilot studies at 19 centers in Australia, Europe and the U.S. showed patients who received renal denervation treatment with the Symplicity system experienced blood pressure reduction at 24 months. The safety of renal denervation with the system was maintained after two years. "These data in nearly twice the number of patients previously reported at two years in this trial provide us with a better understanding of the patient response over time and add to the growing body of evidence supporting the safety and sustained blood pressure reduction of renal denervation treatment with the Symplicity system," said Markus Schlaich, professor of medicine and head of hypertension and kidney disease at the Baker IDI Heart and Diabetes Institute in Melbourne, Australia.
Free e-BOOK on Day Trading with confirmed subscription to our Free Weekly MarketNews newsletter.
Options Trading Room open to subscribers on Monday, October 22, 2012
One week trial to our Day Trading Rooms for stocks, futures, forex and futures. Professional Training Programs available for stocks, futures and forex traders.
Stocks trading calls focus on NYSE, NASDAQ and AMEX.
Futures trading calls focus on YM, NQ, TF and ES.
Forex trading calls based on New York trading session focus on GBPUSD, USDCAD, USDJPY, EURUSD, GBPJPY, USDCHF, EURJPY, EURAUD, AUDJPY, CHFJPY, EURCAD, GBPCAD and AUDUSD.
Detailed historic performance for all calls is available on our Market Commentary page.
Opt-in to our free Weekly MarketNews sent via email, first trading day of the week which includes recap of markets from previous week and what is ahead for the upcoming trading week.
Monthly Trading Lesson provides new trading subject every month.
Register now for our Free Chat Rooms - penny stocks, options, stocks, futures and forex! Chat with other traders during off-peak market hours.
Thanks for reading